Table 3.
Comparison of baseline characteristics between controls and IS patient subgroups with RI
| Control (n=164) | iLAA (n=83) | Test Value | P value | iSAO (n=76) | Test Value | P value | |
|---|---|---|---|---|---|---|---|
| Age | 62.74±14.02 | 76.33±9.98 | -7.182 | <0.001 | 76 73.09±10.21 | -5.634 | <0.001 |
| Gender | 81 (49.39%) | 52 (62.65%) | 3.899 | 0.048 | 49 (64.47%) | 4.759 | 0.029 |
| Smoking | 30 (18.29%) | 43 (51.81%) | 29.731 | <0.001 | 18 (23.68%) | 0.944 | 0.331 |
| TIA/Stroke | -- | 21 (25.30%) | -- | -- | 17 (22.37%) | -- | -- |
| HP | 76 (46.34%) | 74 (89.16%) | 42.360 | <0.001 | 64 (84.21%) | 30.641 | <0.001 |
| DM | 26 (15.85%) | 29 (34.94%) | 11.598 | 0.001 | 25 (32.89%) | 9.012 | 0.003 |
| CVD | 5 (3.05%) | 10 (12.05%) | 7.825 | 0.005 | 9 (11.84%) | 5.797 | 0.016 |
| SBP | 137.79±17.24 | 153.32±24.47 | -5.346 | <0.001 | 151.67±25.39 | -4.462 | <0.001 |
| DBP | 79.38±10.71 | 79.00±14.10 | -0.179 | 0.858 | 82.01±15.28 | -0.971 | 0.332 |
| FPG | 5.08 (4.73, 5.62) | 6.15 (5.17, 8.02) | -4.274 | <0.001 | 5.29 (4.75, 6.17) | -0.522 | 0.602 |
| LDL-C | 2.99±0.78 | 2.96±1.16 | -1.045 | 0.296 | 3.01±1.03 | -0.416 | 0.678 |
| eGFR | 113.37 (90.71, 131.37) | 74.32 (55.30, 81.79) | -10.975 | <0.001 | 78.38 (70.81, 86.65) | -10.055 | <0.001 |
| FA | 1537.9 (6.00, 11.65) | 5.75 (4.22, 8.48) | -3.865 | <0.001 | 5.45 (3.83, 8.45) | -3.578 | <0.001 |
| VitB12 | 319.50 (223.00, 436.00) | 261.50 (194.00, 363.00) | -2.340 | 0.019 | 289.50 (186.30, 349.80) | -2.065 | 0.039 |
| tHCY | 14.85 (12.60, 16.80) | 19.70 (16.80, 23.50) | -7.140 | <0.001 | 18.90 (17.10, 23.40) | -7.105 | <0.001 |
HP, hypertension; DM, diabetes mellitus; CVD, cardiovascular disease; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; LDL-C, low density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; FA, folic acid; VitB12, vitamin B12; tHCY, total homocysteine.